Page 1

August 9 , 2021 Adaptimmune TRANSFORMING T CELL THERAPY Adaptimmune Reports Second Quarter Financial Results and Business Update - SPEARHEAD - 1 data presented at ASCO with overall response rate of 39.3 % in synovial sarcoma and MRCLS ; on track to file BLA for afami - cel next year - - SURPASS trial data from 23 evaluable patients to be presented at ESMO - -ADP - A2AFP Phase 1 trial data from 11 evaluable patients in Group 3 / Expansion to be presented at ILCA - - Financial guidance confirmed : funded into early 2023 - Conference call to be held today at 4:30 p.m. EDT ( 9:30 p.m. BST ) - PHILADELPHIA and OXFORDSHIRE , United Kingdom , Aug. 09 , 2021 ( GLOBE NEWSWIRE ) -- Adaptimmune Therapeutics plc ( Nasdaq : ADAP ) , a leader in cell therapy to treat cancer , today reported financial results for the second quarter ended June 30 , 2021 and provided a business update . " With the data presented at ASCO for afami - cel and our planned BLA filing next year , I am pleased with progress on our ‘ 2-2-5-2 ' strategy , " said Adrian Rawcliffe , Adaptimmune's Chief Executive Officer . “ We will present data updates from our Phase 1 trials , SURPASS and ADP - A2AFP , at upcoming conferences and I am confident that Adaptimmune is well - placed to maintain its leadership position in cell therapies for cancer . " Upcoming confirmed data updates ADP - A2AFP Phase 1 Trial at ILCA • On Sunday , September 5 , 2021 , Dr. Bruno Sangro of Clinica Universidad de Navarra will present data from Cohort 3 and the expansion phase of the Phase 1 trial of ADP- A2AFP in liver cancer during an oral presentation scheduled for 12:25 p.m. CET at the International Liver Cancer Association's ( ILCA ) Annual Conference 。 As of the April 5th data cut - off used for ILCA , 13 patients had received ADP- A2AFP in Cohort 3 and expansion , 11 patients were evaluable with at least one post - baseline scan SURPASS Phase 1 Trial at ESMO • The Company will present an update from its Phase 1 SURPASS trial in an e - poster at the European Society for Medical Oncology ( ESMO ) congress that will be available online September 16th 。 As of the August 2nd data cut - off , 25 patients had received ADP - A2M4CD8 , 23 patients had at least one post - baseline scan 。 The trial continues to recruit in lung , gastroesophageal , head and neck , and